Updated Data Presented for KN026 comboKN046 in 1st Line HER2-Positive Gastric/Gastroesophageal Junction Cancer (GC/GEJ)
As of January 30, 2022,31 patients with HER2-positive unresectable locally advanced or metastatic GC/GEJ, with no prior systemic treatment, were enrolled. 27 patients were evaluable for efficacy. The ORR was 77.8% and DCR was 92.6%. The phase III pivotal study is planned to confirm the efficacy and safety of KN026/KN046 combo as the 1st line treatment for Her2...
Antengene Unveils Its First Australian Office to Continue Expanding Global Presence
SHANGHAI and HONG KONG, Sept. 14, 2022 /PRNewswire/ -- Antengene recently unveiled a new office space situated in Melbourne, Australia's most sought-after CBD, taking another important step in the company's continued global expansion. The new office offers an appealing environment that will help Antengene to attract more top talents, and further accelerate its...
Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence
Debiopharm Innovation Fund strategically invests in Whitelab Genomics' mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future LAUSANNE, Switzerland, Sept. 14, 2022 /PRNewswire/ -- Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm (www.Debiopharm.com), announced today their investment in Whitelab Genomics alongside French Venture Capital company,...
New Study by Lunit and MGH Validates Effectiveness of AI as Aid in Chest X-Ray Interpretation – Published in JAMA Network Open
Joint study with Massachusetts General Hospital proves that Lunit's AI-powered chest x-ray analysis software enhances the overall performance and efficiency of radiologists SEOUL, South Korea, Sept. 13, 2022 /PRNewswire/ -- A recent study published in JAMA Network Open demonstrated that Lunit INSIGHT CXR, Lunit's AI-powered chest x-ray analysis solution, can significantly...
TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism
BIRMINGHAM, England, Sept. 13, 2022 /PRNewswire/ -- Concept Medical announces the successful completion of the TRANSFORM 1 RCT (TReAtmeNt of Small coronary vessels: Randomized controlled trial FOR MagicTouch Sirolimus Coated Balloon). The Randomized Controlled Trial (RCT) was conceptualized with the aim of understanding how the treatment indications and applications of Drug Coated Balloon...
AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib/II Protocol Amendment for ABT-101
An oral Tyrosine Kinase Inhibitor of HER2 Exon20 Insertion, for the Treatment of Non-Small Cell Lung Cancer TAIPEI, Sept. 13, 2022 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotech company designing and developing precision oncology therapies to improve the life of patients, announces today that U.S. Food and Drug Administration (FDA) has approved an investigational new drug (IND) protocol amendment...
EDGC (Eone Diagnomics Genome Center) recruits Sam Martin, Vice President of Overseas Business Development… to “accelerate entering the overseas market”
An expert from Invitae and Ambry Genetics, U.S. genome analysis companies EDGC states, "We will expand the overseas genome analysis market and advance into the global liquid biopsy technology market by recruiting a global talent in the genome field" Worked in a non-profit research organization (ShareGenome) with EDGC CEO Lee Min-Seob SAN DIEGO, Sept. 13, 2022 /PRNewswire/...
Turn Biotechnologies launches eTurna™ delivery platform designed specifically to enable nucleic acid therapeutics
The proprietary platform is versatile, equally effective with different cargoes, routes of administration MOUNTAIN VIEW, Calif., Sept. 13, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced it has created a novel platform to safely and effectively deliver nucleic acid therapeutics – a major expansion of the...
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome
GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting with the Center for Drug Evaluation (CDE) of China's National Medical Products...
INDEPENDENT SCIENTIFIC STUDY DEMONSTRATES PFAS IS NOT IDENTIFIED OR LEACHED IN IPACKCHEM ADVANCED IN-MOLD FLUORINATED CONTAINERS
PARIS, Sept. 13, 2022 /PRNewswire/ -- An independent study designed and overseen by Environmental Standards, Inc. and conducted by Pace Analytical Services LLC found that no PFAS were identified or found to leach into the contents of IPACKCHEM's proprietary Advanced In-Mold Fluorinated (IMF) containers. "This study confirms that IPACKCHEM's Advanced IMF barrier...
